The new MDR compliance challenge

Paul Hercock
The new MDR compliance challenge

26th May 2021 marks the end of the transition period from the old Medical Device Directive (MDD) to the new Medical Device Regulation (EU) 2017/745.

From this date, the MDR will be in full effect and EU-based medical device manufacturers will be required to provide updated technical documentation to meet the standards of the new legislative framework.

Across the industry, medical device companies are facing challenges in meeting the demands of the new legislative framework. Long-held claims of equivalence are no longer valid and the need to evidence every indication is placing huge demands on evidence-generation systems that are difficult to meet.

Why has the Medical Device Directive (MDD) been replaced?

Although generally robust and relatively permissive of innovation, the MDD was considered to have numerous flaws in enforcing medical device safety, reliability and general product quality, exposed by notorious incidents such as the metal-on-metal hip scandal. Legislators were compelled to implement reform.

The new MDR attempts to reduce the likelihood of future incidents of this nature by tightening the requirements for proving safety and effectiveness of all medical devices, regardless of how long the product has been on the market.

How will the industry be affected?

From an industry perspective, the most important changes are the need to provide evidence “on an ongoing basis” to support every individual indication, in parallel with the reduced capacity to claim equivalence to devices already approved for sale.

These changes mean that manufacturers across the industry face a significantly increased evidence-generation burden, meaning a potentially huge increase in cost to meet the demands for medical device compliance. In some cases, this may even challenge the commercial viability of a product.

How can Mantra Systems help you?

We are experts at supporting medical device manufacturers with all elements of the MDR and will ensure that you have the systems in place to meet the demands of the new legislation.

Our MedDev 2.12-based systems ensure full harmonization of data collection standards across multiple locations in full adherence to GDPR and all relevant ISO standards. We will work with you to design and develop your PMCF System to the highest level of legal and regulatory compliance.

Related articles

  1. US and EU flags on poles alongside each other.

    Clinical Evidence under EU MDR: Leveraging FDA Clinical Data to Streamline EU MDR Compliance

    FDA approval alone is not sufficient for European market access - a theme we explore futher in this article and the accompanying webinar.

    Chandini Valiya Kizhakkeveetil Chandini Valiya Kizhakkeveetil Regulatory Medical Writer
  2. An AI-generated image of 3 people in an office in front of a whiteboard with the words 'Medical Device Market Entry Strategy' written above a world map.

    EU MDR & NHS DTAC Cybersecurity Requirements for UK Market Entry

    This guest article from our partner Cyber Alchemy shows you how to build cybersecurity evidence for the EU MDR and NHS DTAC.

    Luke Hill Luke Hill Co-Founder of Cyber Alchemy
  3. An illustration showing a GPS-driven navigation route superimposed upon someone using a laptop.

    Where to Launch First? A MedTech Founder's Regulatory Roadmap to the EU, UK and US

    Cyber Alchemy × Mantra Systems — Episode 1: All three markets operate under different regulatory systems and place different demands on manufacturers.

    Ronghe Xu Ronghe Xu Regulatory Medical Writer & Strategic BD Lead China
  4. A woman uses an inhaler.

    Navigating EU MDR Article 117: A Practical Guide to Drug-Device Combination Product Submissions

    Implementation of the EU MDR 2017/745 has brought significant changes.

    Chandini Valiya Kizhakkeveetil Chandini Valiya Kizhakkeveetil Regulatory Medical Writer
  5. Collage art showing a pair of binoculars, an analogy for surveillance.

    How EU MDR Post Market Surveillance differs from FDA post-market expectations

    We compare manufacturer-specific post-market obligations across both regulatory systems.

    Dr Gayle Buchel Dr Gayle Buchel Chief Medical Writer
  6. An arrow arcs from the US over to Europe.

    How EU device classification differs from the US - Are you Prepared?

    Did you know an FDA Class II medical device could be immediately considered as a high-risk Class III device under European Union regulations?

    Gabriela Cardoso Gabriela Cardoso Regulatory Medical Writer
  7. A magnifying glass inspecting a number of wooden cubes with question marks upon them laid upon a blue table. The wooden cube under the magnifying glass has a lightbulb painted on it.

    Fixing the MDR and IVDR? The Commission’s Proposed Amendments and What They Mean for Manufacturers

    Exploring the key elements of this proposal.

    Chandini Valiya Kizhakkeveetil Chandini Valiya Kizhakkeveetil Regulatory Medical Writer
  8. Two arms point at a sign and hold a question mark, in an abstract pop-art style.

    Regulatory Reset? The EU’s Proposed Changes to MDR and IVDR Explained

    Changes published in December 2025 aim to streamline EU medical device and in vitro diagnostics. We explain who is impacted and how.

    Dr Gayle Buchel Dr Gayle Buchel Chief Medical Writer
  9. A pair of glasses rests on an eye test chart.

    Did You Know Your Glasses Were a Medical Device? A Regulatory Guide for Manufacturers

    The importance of correct classification and our recommended path to avoid common ophthalmic device 'gotchas'.

    Gabriela Cardoso Gabriela Cardoso Regulatory Medical Writer

More articles

Need help producing compliant CEPs & CERs? We are offering FREE CEPs to 5 qualifying applicants per week

Get your free CEP